N/A
Completed N=330
A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in Japan
Source: ClinicalTrials.gov NCT05882279 ↗Enrolled (actual)
330
Serious AEs
—
Results posted
Jun 2024
Primary outcomePrimary: Number of Pharmacists Who Had Provided Patients With the Contents of the Risk Management Plan (RMP) Material — 307 Participants
Summary
This is a survey among pharmacists who have instructed NINLARO therapy in ixazomib, lenalidomide and dexamethasone (IRD) dosing to patients with relapsed/refractory multiple myeloma (rrMM).
The main aims of the study are:
* To assess the frequency of pharmacists who have provided patients with the contents of the RMP material for patients.
* To assess the frequency of pharmacists who have obtained the RMP material for patients.
* To evaluate the depth of understanding of proper usage of NINLARO among pharmacists.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Pharmacists Who Had Provided Patients With the Contents of the Risk Management Plan (RMP) Material |
307 | — |
| SECONDARY Number of Pharmacists Who Had Received the RMP Material for Patients |
124 | — |
| SECONDARY Number of Pharmacist With Understanding of the Proper NINLARO Dosing Schedule |
316 | — |
| SECONDARY Number of Pharmacist With Understanding of the Importance of Providing NINLARO Dosing Schedule |
298; 30; 1; 1 | — |
Eligibility Criteria
Inclusion criteria
- Who belong to hospitals prescribing NINLARO.
- Who have instructed the dosing of NINLARO in IRD therapy to patients.
Exclusion criteria
None
Data sourced from ClinicalTrials.gov (NCT05882279). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.